The Brexit effect: clinical trials and new drug approvals
This article was originally published in SRA
Executive Summary
A UK departure from the EU could deprive pharmaceutical companies of the advantages offered by European harmonization in the area of clinical trials and marketing authorizations, say Jane Summerfield and Amy Merrick.